Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Regeneron Pharmaceuticals (NQ: REGN )

461.57 USD +12.19 (+2.71%)
Official Closing Price Updated: 7:58 PM EST, Mar 5, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Stories about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
4 SPACs for the Future
A rocket company, a 3-D capture software company, and two biotechs are about to hit the public markets. Smart investors can get in now via special purpose acquisition companies. 
Tags REGN H GSK
From Motley Fool
Is BioNTech Stock a Buy?
The key ingredients are here for a multi-bagger over the next decade and beyond. 
Tags PFE BNTX Market News
From Motley Fool
The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ... 
Tags ABUS Earnings LHDX
From Benzinga
Sanofi/Regneron's Dupixent Application For Asthma In Children Accepted For FDA Review
TheFDA has accepted for reviewthe supplemental marketing application seeking approval for Dupixent (dupilumab). It is an ... 
Tags Benzinga Market News SNY
From Benzinga
Vir Stock Craters On Weak Data For GSK-Partnered Covid Treatment
Emerging data cast doubt on the effectiveness of Vir Biotechnology and GlaxoSmithKline's coronavirus treatment, leading Vir stock to plummet on Wednesday. Shares plunged more than 30%. 
From Investor's Business Daily
ACWV, WM, REGN, GILD: Large Outflows Detected at ETF
Symbols mentioned in this story: ACWV, WM, REGN, GILD Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units''... 
Tags ETFs
From ETF Channel
Noteworthy Monday Option Activity: RAD, REGN, HURN
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Rite Aid Corp (RAD), where a total volume of 19,413 contracts has been traded thus... 
Tags Stocks
From Market News Video
Regeneron's Single-Dose REGN1908-1909 Shows Rapid, Durable Benefit In Cat-Allergic Asthma Patients
Regeneron Pharmaceuticals Inc(NASDAQ:REGN) hasannounced detailed resultsfrom a Phase 2 proof-of-concept trial ... 
Tags Market News Benzinga Biotech
From Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
Most Food and Drug Administration decisions scheduled for February were positive, and more importantly five new molecular entities ... 
Tags MNKKQ KMPH PFE
From Benzinga
Retail, Tech Earnings, and Berkshire's Surprising Buys
Our Fools talk about fourth-quarter results, as well as the loss of a great CEO. 
Tags TTD SHOP ABNB
From Motley Fool
Regeneron's COVID-19 Antibody Cocktail Wins EU Positive Opinion
Regeneron Pharmaceuticals Inc(NASDAQ:REGN) hasreceived a positive opinionfrom European Medicines Agency's ... 
Tags News General REGN
From Benzinga
First Week of REGN August 20th Options Trading
Investors in Regeneron Pharmaceuticals, Inc. (REGN) saw new options become available this week, for the August 20th expiration.. 
Tags Stocks
From Market News Video
Coronavirus Mutations: Why The Battle Against Covid Is Just Beginning
The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals. 
From Investor's Business Daily
Akari Therapeutics' PASylated Nomacopan Shows Promising Action In Animal Studies
Akari Therapeutics Plc(NASDAQ:AKTX)announces new datafrom PASylated nomacopan published in the journal ... 
Tags Penny Stocks AKTX News
From Benzinga
Positive news on COVID vaccines weighs against concerns over new variants
The COVID-19 vaccine developed by Pfizer Inc. and German partner BioNTech SE has proved to be as effective in the real world as it was in clinical trials in the first major study of the two-dose... 
Tags PFE DJIA BNTX
From MarketWatch
Regeneron To Stop Giving Placebo In COVID-19 Antibody Trial After 'Clear Efficacy'
Following recommendationsfrom the Independent Data Monitoring Committee (IDMC),Regeneron Pharmaceuticals ... 
Tags Benzinga Market News Covid/19
From Benzinga
Decibel Therapeutics' Hearing Loss Gene Therapy Shows Potential In Preclinical Studies
Decibel Therapeutics Inc(NASDAQ:DBTX)presented preclinical dataof its gene therapy candidate, DB-OTO, for ... 
Tags Biotech Phase 1 Trial Health Care
From Benzinga
RLFTF: Why Little-Known Relief Therapeutics Is Climbing Today
<p><a rel="nofollow" href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice & Trading Tips</a></p> <p>Shares of little-known biopharma firm Relief Therapeutics gained on... 
Tags RLFTF LLY CDMO
From InvestorPlace
Opthea Outlines OPT-302 Pivotal Study Designs In Chronic Eye Disorder
Following consultations with FDA and European Medical Agency,OptheaNASDAQ: OPT) hasfinalized trial designsfor ... 
Tags Benzinga RHHBY RHHVF
From Benzinga
Why You Should Keep Your Distance from Ocugen Stock
<p><a rel="nofollow" href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice & Trading Tips</a></p> <p>Off and on the price chart OCGN stock, today's reality is bleak for... 
Tags MRNA NASDAQ:OCGN,NYSE:PFE,NYSE:JNJ,NASDAQ:REGN,NYSE:AZN,NASDAQ:MRNA PFE
From InvestorPlace
Sanofi/Regeneron's DUPIXENT Wins Canada Approval For Atopic Dermatitis In Children Aged 6-11
Health Canada has approvedSanofi’s SA(NASDAQ:SNY) andRegeneron Pharmaceuticals ... 
Tags News REGN General
From Benzinga
2 Best Pharma Stocks to Buy Right Now
These under-appreciated pharma stocks have the potential to become long-term winners. 
Tags MYL ABBV Market News
From Motley Fool
FDA Approves Regeneron/Sanofi's Libtayo For Front-Line Lung Cancer
The FDA approved expanded use ofRegeneron Pharmaceuticals Inc(NASDAQ:REGN) andSanofi’s ... 
Tags SNY A REGN
From Benzinga
Should You Follow Cathie Wood Into This Coronavirus Stock?
This latest pick has been sluggish so far -- but the long-term opportunity may be huge. 
Tags Market News ARKF REGN
From Motley Fool
Should Investors Worry About Moderna's Vaccine Delays?
The short answer: No. 
Tags MRNA REGN CTLT
From Motley Fool
Implied HIPR Analyst Target Price: $68
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
What Are the Long-Term Prospects for Moderna?
The biotech's messenger RNA platform is promising. But some investors could have qualms about its current valuation. 
Tags PFE REGN MRNA
From Motley Fool
AbbVie Posts A Massive Growth Quarter — Is It Time To Add AbbVie Stock?
AbbVie stock was within a buy zone in mid-February after the company topped fourth-quarter views and issued upbeat 2021 guidance. The company also has the option to buy Cypris Medical. 
From Investor's Business Daily
3 Reasons to Buy Ocular Therapeutix Stock Right Now
There are a few reasons this could be the best biotech stock you can buy at the moment. 
Tags REGN PFE OCUL
From Motley Fool
Better Coronavirus Stock: Inovio Pharmaceuticals vs. Vaxart
The choice isn't easy, but simplicity may be the answer. 
Tags REGN JNJ INO
From Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.